Advertisement

Both non-surgical dental treatment and extractions increase the risk of medication-related osteonecrosis of the jaw: case-control study

  • Kelly McGowanEmail author
  • Robert S. Ware
  • Caroline Acton
  • Saso Ivanovski
  • Newell W. Johnson
Original Article

Abstract

Objectives

Medication-related osteonecrosis of the jaws (MRONJ) is a serious condition whose risk factors remain unclear. The aim of this study is to investigate the role of oral health and of dental treatment in the development of MRONJ.

Materials and methods

A case-control study was conducted in Brisbane, Australia. Hospital records were used to identify incident cases of MRONJ between January 2010 and March 2017. Cases were individually matched to up to 3 controls according to age, sex, primary disease, and type of antiresorptive therapy. Demographic data, medical histories and public dental records were collected. Associations between oral health, dental treatment, and MRONJ were investigated using conditional logistic regression.

Results

Overall, 44 cases were identified and matched to 115 controls (total sample = 159). Only one-third of patients received a dental examination in the year prior to commencing antiresorptive therapy (27% of cases and 34% of controls). After adjusting for potentially confounding variables, non-surgical dental treatment (OR = 6.3; 95% CI = 2.1, 19.1; p < 0.001) and dental extractions (OR = 8.0; 95% CI = 3.0, 21.0, p < 0.001) were significantly associated with development of MRONJ.

Conclusions

Current levels of preventative dental care are insufficient to eliminate the need for dental treatment and extractions during antiresorptive therapy, and the consequent increase in risk of MRONJ.

Clinical relevance

Optimizing the health of the oral cavity and ongoing preventative dental care must be a priority for patients prior to the initiation of antiresorptive medications.

Keywords

Risk assessment Bone density conservation agents Cancer Osteoporosis Dental procedure Preventative dentistry 

Notes

Compliance with ethical standards

Conflict of interest

K McGowan has received a speaker honorarium from Eli Lilly. RS Ware declares that he has no conflict of interest. C Acton declares that she has no conflict of interest. S Ivanovski declares that he has no conflict of interest. NW Johnson declares that he has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

For this type of study, formal consent is not required.

Supplementary material

784_2019_2828_MOESM1_ESM.docx (23 kb)
ESM 1 (DOCX 23.0 kb)

References

  1. 1.
    Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72(10):1938–1956CrossRefGoogle Scholar
  2. 2.
    Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the allied task force committee of Japanese society for bone and mineral research, Japan osteoporosis society, Japanese society of periodontology, Japanese society for oral and maxillofacial radiology, and Japanese society of oral and maxillofacial surgeons. J Bone Miner Metab 28(4):365–383CrossRefGoogle Scholar
  3. 3.
    Niibe K, Ouchi T, Iwasaki R, Nakagawa T, Horie N (2015) Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab. J Prosthodont Res 59(1):3–5CrossRefGoogle Scholar
  4. 4.
    Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW (2008) Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 66(4):767–775CrossRefGoogle Scholar
  5. 5.
    McGowan K, McGowan T, Ivanovski S (2018) Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 24(4):527–536CrossRefGoogle Scholar
  6. 6.
    Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27(32):5356–5362CrossRefGoogle Scholar
  7. 7.
    Jadu F, Lee L, Pharoah M, Reece D, Wang L (2007) A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 18(12):2015–2019CrossRefGoogle Scholar
  8. 8.
    Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826–836CrossRefGoogle Scholar
  9. 9.
    Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, Kondou E, Takeda D, Kojima Y, Sato S (2017) A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int 28(8):2465–2473CrossRefGoogle Scholar
  10. 10.
    Tsao C, Darby I, Ebeling PR, Walsh K, O’Brien-Simpson N, Reynolds E, Borromeo G (2013) Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg Surg 71(8):1360–1366CrossRefGoogle Scholar
  11. 11.
    Barasch A, Cunha-Cruz J, Curro F, Hujoel P, Sung A, Vena D, Voinea-Griffin A, Group CC (2011) Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 90(4):439–444CrossRefGoogle Scholar
  12. 12.
    Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A (2008) Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 13(8):911–920CrossRefGoogle Scholar
  13. 13.
    Matsui A, Kurihara J, Morishima H, Suzuki H, Sato S, Yamauchi K, Takahashi T (2015) Medication related osteonecrosis of the jaw (MRONJ): a retrospective survey of a series of patients treated according to the AAOMS guidelines. J Oral Maxillofac Surg Med Pathol 27(6):757–763CrossRefGoogle Scholar
  14. 14.
    Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Initiative S (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med 45(4):247–251CrossRefGoogle Scholar
  15. 15.
    Ripamonti C, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2008) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20(1):137–145CrossRefGoogle Scholar
  16. 16.
    Australian Bureau of Statistics [ABS], Census of population and housing: Socio-economic indexes for areas (SEIFA), Australia, 2016. Canberra: Australian Bureau of Statistic, 2018. [Updated 2018 March 27; cited 2018 July 30]. Available from: http://www.abs.gov.au/ausstats/abs@.nsf/mf/2033.0.55.001
  17. 17.
    Dimopoulos M, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E (2008) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20(1):117–120CrossRefGoogle Scholar
  18. 18.
    Mücke T, Deppe H, Hein J, Wolff KD, Mitchell DA, Kesting MR, Retz M, Gschwend JE, Thalgott M (2016) Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid – a prospective study over 6 years. J Craniomaxillofac Surg 44(10):1689–1693CrossRefGoogle Scholar
  19. 19.
    Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3–23CrossRefGoogle Scholar
  20. 20.
    Sambrook PN, Chen JS, Simpson JM, March LM (2010) Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust 193(3):154–156Google Scholar
  21. 21.
    Chan BH, Yee R, Puvanendran R, Ang S (2018) Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. Singap Med J 59(2):70–75CrossRefGoogle Scholar
  22. 22.
    Toh CL, Dutton A (2018) Comment on: medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. Singap Med J 59(5):287CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.School of Dentistry and Oral HealthGriffith UniversitySouthportAustralia
  2. 2.School of DentistryUniversity of QueenslandHerstonAustralia
  3. 3.Menzies Health Institute QueenslandGriffith UniversitySouthportAustralia
  4. 4.Oral and Maxillofacial Surgery DepartmentRoyal Brisbane and Women’s HospitalHerstonAustralia
  5. 5.Dental InstituteKing’s College LondonLondonUK

Personalised recommendations